



Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study

Falko Tesch¹ · Franz Ehm¹ · Annika Vivirito² · Danny Wende³ · Manuel Batram⁴ · Friedrich Loser⁵ · Simone Menzer⁶ · Josephine Jacob² · Martin Roessler³ · Martin Seifert¹ · Barbara Kind¹ · Christina König⁵ · Claudia Schulte³ · Tilo Buschmann⁷ · Dagmar Hertle³ · Pedro Ballesteros³ · Stefan Baßler⁷ · Barbara Bertele⁵ · Thomas Bitterer⁶ · Cordula Riederer⁸ · Franziska Sobik⁸ · Lukas Reitzle⁹ · Christa Scheidt-Nave⁹ · Jochen Schmitt¹

Received: 25 January 2023 / Revised: 11 May 2023 / Accepted: 8 June 2023 / Published online: 19 June 2023
© The Author(s) 2023, corrected publication 2023

Abstract

Objectives To investigate whether the risk of developing an incident autoimmune disease is increased in patients with prior COVID-19 disease compared to those without COVID-19, a large cohort study was conducted.

Method A cohort was selected from German routine health care data. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020. Patients were matched 1:3 to control patients without COVID-19. Both groups were followed up until June 30, 2021. We used the four quarters preceding the index date until the end of follow-up to analyze the onset of autoimmune diseases during the post-acute period. Incidence rates (IR) per 1000 person-years were calculated for each outcome and patient group. Poisson models were deployed to estimate the incidence rate ratios (IRRs) of developing an autoimmune disease conditional on a preceding diagnosis of COVID-19.

Results In total, 641,704 patients with COVID-19 were included. Comparing the incidence rates in the COVID-19 (IR=15.05, 95% CI: 14.69–15.42) and matched control groups (IR=10.55, 95% CI: 10.25–10.86), we found a 42.63% higher likelihood of acquiring autoimmunity for patients who had suffered from COVID-19. This estimate was similar for common autoimmune diseases, such as Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome. The highest IRR was observed for autoimmune diseases of the vasculitis group. Patients with a more severe course of COVID-19 were at a greater risk for incident autoimmune disease.

Conclusions SARS-CoV-2 infection is associated with an increased risk of developing new-onset autoimmune diseases after the acute phase of infection.

Key Points

- In the 3 to 15 months after acute infection, patients who had suffered from COVID-19 had a 43% (95% CI: 37–48%) higher likelihood of developing a first-onset autoimmune disease, meaning an absolute increase in incidence of 4.50 per 1000 person-years over the control group.
- COVID-19 showed the strongest association with vascular autoimmune diseases.

Keywords Autoimmune diseases · Claims data · Cohort study · COVID-19 · SARS-CoV-2

✉ Falko Tesch
Falko.tesch@ukdd.de

¹ Center for Evidence-Based Healthcare (ZEGV), University Hospital and Faculty of Medicine Carl Gustav Carus at TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany

² InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany

³ BARMER Institut für Gesundheitssystemforschung (bifg), Berlin, Germany

⁴ Vandage GmbH, Bielefeld, Germany

⁵ Techniker Krankenkasse, Hamburg, Germany

⁶ IKK classic, Dresden, Germany

⁷ AOK PLUS, Dresden, Germany

⁸ DAK-Gesundheit, Hamburg, Germany

⁹ Robert Koch Institute, Berlin, Germany

Introduction

Numerous research articles have been published to date on COVID-19, the acute disease that results from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its chronic counterpart long/post-COVID. SARS-CoV-2 is a positive-polar single-stranded RNA (ssRNA) virus that is transmitted directly by respiratory droplets [1]. After the acute phase of infection, some people develop long-lasting symptoms, known as post-COVID. This is defined by signs and symptoms that develop during or after SARS-CoV-2 infection that are consistent with COVID-19, last more than 12 weeks and cannot be explained by an alternative diagnosis [2]. Most studies so far have focused on symptoms that partly resolve over time [3–7]. Many studies examined a small selective sample of patients, and only a few studies included a control group or information on chronic health conditions, such as SARS-CoV-2 infection [8]. The recent evidence is insufficient to estimate the burden of COVID-19 in a population and the resulting future challenges to health care systems. Routinely collected health data, such as claims data from health insurances, offer large sample sizes to investigate rare but potentially severe outcomes in this context.

To date, different respiratory, cardiovascular, neurological, and mental diseases as well as various symptoms in the context of long/post-COVID have been studied with routine health care data [9–16]. The group of autoimmune diseases is less discussed in the literature, although autoantibodies could be found in patients after SARS-CoV-2 infection, e.g., anti-type I IFNs, anti-IFN- α , and anti-nuclear antibodies (ANAs) [17]. So far there is limited evidence on newly manifested autoimmune diseases after an infection based on several case reports and two recent cohort studies [18–21]. Furthermore, COVID-19 itself shares some similarities with systemic autoimmune rheumatic diseases, which could be a challenge for diagnostics [22, 23].

Here, we investigated the association of COVID-19 and a set of incident autoimmune diseases in a large cohort of patients enrolled in German statutory health insurances.

Methods

Study design

We conducted a matched cohort study based on routine health care data as applied in a previous study [14]. In the present analysis, we compared the rates of newly diagnosed autoimmune disease between individuals with and without documented SARS-CoV-2 infection. Persons infected with SARS-CoV-2 during 2020 and matched controls were followed until June 30, 2021, for a minimum of three and a

maximum of 15 months using the date of COVID-19 onset as the index date for randomly selected match groups. Following the NICE guidelines on long COVID [24] and the clinical case definition of post-COVID-19 conditions proposed by the World Health Organization (WHO) [2], we defined the post-COVID-19 phase starting 3 months after the initial diagnosis of COVID-19. Outpatient services are documented per quarter rather than on a daily basis in the German statutory health care billing system. We therefore considered a diagnosis to have been made in the post-COVID-19 phase if it was newly documented in the second quarter after the index date or later. This operationalization ensures a time interval of at least 3 months between the date of COVID-19 diagnosis and post-COVID-19 outcome incidence.

Cohorts

The COVID-19 cohort included individuals with polymerase chain reaction (PCR)-confirmed COVID-19 diagnosis (ICD-10 U07.1) in 2020. To calculate risk exposure time, we defined the onset of COVID-19 inside the quarter as the index date by using the date of an outpatient PCR test or the date of admission to a hospital with a COVID-19 diagnosis. The control cohort included individuals who were not diagnosed with ICD-10 U07.1 or ICD-10 U07.2 without a documented COVID-19 diagnosis between January 1st, 2020, and June 30th, 2021.

We excluded individuals with COVID-19 diagnosis without laboratory virus detection (ICD-10-GM: U07.2) from the COVID-19 groups and non-COVID-19 controls to reduce distortions due to misclassification. We further excluded individuals who were not continuously registered with the respective health insurance company between 2019-01-01 (or birth) and 2021-06-30 (or death), whichever came first, because relevant outcomes and preexisting health conditions may not be visible in our data. For each individual, preexisting medical conditions could be assessed for at least 12 months prior to the matching point of the COVID-19 and control cohorts. Starting from the index date, which was assigned from the COVID-19 case, matched individuals were jointly followed for a maximum of 15 months. This permitted comparison of two groups over the same period to compare their risk of developing any of the predefined incident autoimmune diseases conditional on COVID-19.

Ethics and registration

The study was approved by the ethics committee of the TU Dresden (approval number: BO-EK (COVID)-482102021) and adheres to all relevant administrative and legal regulations. The study was registered at [ClinicalTrials.gov](https://www.clinicaltrials.gov) (NCT number: NCT05606198).

Data

The underlying data sources were set up for the “Post-COVID-19 Monitoring in Routine Health Insurance Data” (POINTED) consortium [14] to study the long-lasting effects of the COVID-19 pandemic in Germany. The POINTED consortium is coordinated by the Center for Evidence-Based Healthcare (ZEGV) at the TU Dresden and consists of the German National Public Health Authority, the Robert Koch Institute, health research institutes, and statutory health insurances. It is funded partly by the German Federal Ministry of Health (BMG).

We used routine health care data from different German statutory health insurances: Techniker Krankenkasse, BARMER, DAK Gesundheit, IKK classic, AOK PLUS, and several company health insurance funds (InGef [25]). In total, these data cover approximately 39 million individuals, which corresponds to nearly half of the total German population. In addition to sociodemographic characteristics (age and sex) and vital status (via the date of death), we had access to comprehensive information on health care utilization in the outpatient and inpatient health care sectors. The data comprise records on diagnoses (according to the International Statistical Classification of Diseases and Related Health Problems - German Modification, ICD-10-GM), medical procedures (according to the “Operationen- und Prozedurenschlüssel,” OPS; German modification of the International Classification of Procedures in Medicine, ICPM), information on outpatient medical services (according to “Einheitlicher Bewertungsstab,” EBM), and prescribed medications (according to the German Anatomical Therapeutic Chemical (ATC) Classification). Only patients from the year 2020 were selected, as this ensured that the effect was not influenced by vaccinations (Vaccination in Germany started as of 27th of December 27, 2020).

Matching

To minimize differences between the COVID-19 and control cohorts in terms of covariates that may confound relationships between outcomes and exposure, we applied 1:3 matching with replacement for COVID-19 to non-COVID-19 patients. For each individual in the COVID-19 cohort, we selected three non-COVID-19 individuals with identical age (in years), sex, and whether or not an autoimmune disease was present before the index date. We chose exact matching on these characteristics to facilitate stratified analysis. In addition, we accounted for the presence of covariates by propensity score matching. The estimation of the propensity score was based on logistic regression including all insured individuals. Given different sets of prevalent medical conditions considered as covariates, we

estimated separate regression models for children/adolescents and adults.

After matching individuals with COVID-19 and controls, we excluded individuals from the match groups if they died before the beginning of the post-COVID phase, i.e., within the quarter of the COVID-19 diagnosis or the following quarter. We also excluded individuals with COVID-19 who lacked a matching partner. When analyzing specific health outcomes, we further excluded individuals from the analysis if the considered outcome was documented in two of the four quarters preceding in the outpatient setting or once in the inpatient setting. To maintain balance of cohorts regarding covariates, we excluded a complete match group of COVID-19 and control cases if the outcome was preexisting for the individual with COVID-19 or all of his or her matched non-COVID-19 control cases. For estimation, we weighted data from individuals in the control cohort with the inverse number of individuals remaining in the respective match group (i.e., weights between 1/3 and 1) to ensure that total weights in the control cohort added up to the number of individuals in the COVID-19 cohort.

Health outcomes

Based on the clinical experience of the author team, we defined 64 potential outcomes from 41 autoimmune diseases studied during follow-up 3 to 15 months after documented COVID-19 infection, e.g., assigned index date. Operationalization of these outcomes was based on inpatient and outpatient diagnoses according to ICD-10-GM. In 23 cases, a more specific definition of the outcome with suitable medication was chosen. For type I diabetes, only those cases with an insulin prescription were considered valid. A complete list of the considered outcomes and their definitions can be found in supplementary material S1.

Covariates

We used information on preexisting chronic conditions as available from 2019 health records to adjust for potential confounders in the relationship of exposure (COVID-19) and incident autoimmune diseases. The approach is similar to a previous study [14].

For each individual, we used information on preexisting health conditions in the four quarters preceding the index date. The 13 prevalent morbidities for children/adolescents and 34 prevalent morbidities were based on published evidence and clinical expertise (supplementary material S2). In addition, we included age, sex, and the number of recorded inpatient and outpatient contacts as covariates. In line with previous studies [9], we included the severity of COVID-19 as a stratification

feature and differentiated between (1) individuals with outpatient diagnoses of COVID-19, (2) individuals with a hospital visit with COVID-19, and (3) individuals with intensive care and/or mechanical ventilation with COVID-19.

Statistical analyses

The incidence rates (IRs) of autoimmune diseases per 1000 person-years were estimated. Differences in IRs between COVID-19 and non-COVID-19 patients were estimated using Poisson regression models to estimate incidence rate ratios (IRRs). As a prerequisite, we derived aggregated information on each health outcome by counting incident cases of the respective autoimmune disease within the COVID-19 and control groups. Since the number of incident cases for each outcome varied across the match groups, we assigned weights to the remaining control cases that added up to 1. The pooling of individual-level data was not possible due to data protection restrictions. The different insurance datasets were therefore analyzed separately by authorized institutes or the health care research departments within the respective health insurances. Each authorized institute calculated the required aggregate statistics and provided them to ZEGV, where regressions based on combined aggregate data were performed.

To synthesize evidence across datasets, we note that point estimates from aggregate matched data are equal compared to the case of Poisson regression based on individual level data [26]. The characteristics of Poisson regression applied to aggregate count data allowed for consistent estimation of incidence rates regardless of the distribution of the outcome

on the individual level when the conditional mean function is correctly specified [27]. However, variance estimates from aggregates tend to be larger, meaning that the statistical significance of the presented effects may be underestimated. Utilizing a main advantage of Poisson regression, we adjusted for differences in individual-specific times at risk (time between the index date and the end of the observation period or death) due to inclusion of these times as offset in the model. Stratified aggregation enabled us to deploy separate estimators for age, sex, prevalent autoimmune disease, and severity of COVID-19. We conducted all analyses using the statistical programming language R version 3.6.2 [28].

Results

Description of the study population

In 2020, 38.9 million individuals were insured in one of the participating insurance companies for at least 1 day. We excluded persons not continuously enrolled in 2019 ($n=2,074,654$) or between January 1st, 2020, and June 30, 2021 ($n=2,051,855$), those with a COVID-19 diagnosis without definite laboratory confirmation (ICD-10 U07.2) ($n=3,549,324$), and those with a COVID-19 diagnosis in the first two quarters of 2021 ($n=569,410$) from the analyses (Fig. 1). From the remaining sample, 670,301 individuals with a COVID-19 diagnosis were matched 1:3 to controls. For 29 individuals with COVID-19 (0.004%), no suitable matching partner was found. After matching, there were 28,810 individuals with COVID-19 and 20,932 control




Fig. 1 Flowchart for the selection of the COVID-19 and control groups

cases who died in the time between the (assigned) index date and the beginning of the second quarter following the (assigned) index quarter. By excluding these cases from the post-COVID-19 observable cohort, an additional 81,570 controls (from 28,810 match groups) and 55 individuals with COVID-19 were left without matching partners and thus had to be excluded from the study. The final study population consisted of 641,407 individuals with COVID-19 and 1,560,357 non-COVID-19 individuals serving as controls in 1,907,992 control cases. Most of the individuals in the COVID-19 group had three control cases. Only minor fractions of individuals with COVID-19 had two ($n=13,187$; 2.06%) or one ($n=869$; 0.14%) control case/s. As sampling with replacement was conducted, the control cohort consisted of only 1,560,357 distinct individuals (Fig. 1).

Description of the population

Among the 641,407 COVID-19 individuals included, 76,518 (11.9%) had a prevalent autoimmune disease prior to COVID-19. Among those without any preexisting autoimmune diagnoses ($N=564,889$), 6489 (1.1%) developed a first autoimmune disease 3 to 15 months after SARS-CoV-2 infection. Of the individuals with preexisting autoimmunity ($N=76,518$), 1744 (2.3%) developed an additional autoimmune disease. More than half of those in the COVID-19 and control cohorts were female (57.3%); the majority were between 18 and 64 years of age (74.2% and 74.6%), while 9.4% and 9.5% were below 18 years of age and 16.3% and 15.9% were 65 years of age or older, respectively. Regarding

the course of the acute COVID-19 disease, 6.4% of individuals were hospitalized, and 1.6% received intensive care treatment and/or mechanical ventilation (Table 1).

Incidence of a new autoimmune disease

The incidence rate (IR) of any autoimmune disease 3 to 15 months after SARS-CoV-2 infection was 15.05 (95% CI: 14.69–15.42) per 1000 person-years in the COVID-19 group and 10.55 (95% CI: 10.25–10.86) in the control group for patients without a prior autoimmune disease. Hence, the excess risk due to SARS-CoV-2 infection was 4.50 per 1000 person-years. The IRR for an incident autoimmune disease was 1.43 (95% CI=1.37–1.48). Furthermore, the IR was higher for individuals with COVID-19 who had any preexisting autoimmune disease, while the relative likelihood to controls with preexisting autoimmune disease was smaller (IR COVID-19=38.10, IRR=1.23 95% CI=1.15–1.32) (Table 2).

From the list of autoimmune diseases, only those who had at least 20 events in the COVID-19 group were further investigated. Thus, 24 of 64 outcomes were excluded from the analysis. The remaining 40 outcomes represented 28 diseases (Table 2). The most common incident autoimmune diseases with an IR above 1 in 1000 person-years in the COVID-19 group were Hashimoto thyroiditis (IR COVID-19 =4.41, IRR=1.42, 95% CI=1.33–1.52), Graves' disease (IR COVID-19=3.52, IRR=1.41, 95% CI=1.31–1.51), psoriasis (IR COVID-19=3.17, IRR=1.17, 95% CI=1.09–1.26), rheumatoid arthritis (IR COVID-19 =2.43, IRR=1.42, 95% CI=1.30–1.56), and Sjögren syndrome (IR

Table 1 Characteristics of COVID-19 and control cohort after matching

Variable	N COVID-19	Percent COVID-19	Controls	Percent control
Total	641,407	100	1,907,992	100
Sex				
Male	273,868	42.7	1,092,873	42.7
Female	367,539	57.3	815,119	57.3
Age				
0–17	60,535	9.4	181,210	9.5
18–64	476,085	74.2	1,423,132	74.6
65–79	60,889	9.5	180,060	9.4
80+	43,898	6.8	123,590	6.5
Severity of COVID-19				
Outpatient	590,204	92.0	-	-
Hospital	40,846	6.4	-	-
ICU/ventilation	10,357	1.6	-	-
Autoimmunity				
Any preexisting autoimmune disease	76,518	11.9	237,035	12.4
First onset of autoimmune disease	6489	1.1	13376	0.8
Additional autoimmune disease with preexisting autoimmunity	1744	2.3	3324	1.4

Table 2 Incidence rate (IR) and incidence rate ratio (IRR) for an autoimmune disease among persons with compared to those without SARS-CoV-2 infection 3 to 15 months after the index date

Outcomes	Events COVID-19	IR COVID-19	Events weighted controls*	IR weighted controls	IRR	95% CI
First onset of autoimmune disease	6489	15.05	4552	10.55	1.43	1.37–1.48
Additional autoimmune disease with preexisting autoimmunity	1744	38.10	1418	30.94	1.23	1.15–1.32
Hashimoto thyroiditis	2089	4.41	1474	3.11	1.42	1.33–1.52
Graves' disease	1696	3.52	1207	2.51	1.41	1.31–1.51
Psoriasis	1519	3.17	1299	2.71	1.17	1.09–1.26
Psoriasis with medication	488	1.00	405	0.83	1.21	1.06–1.38
Rheumatoid arthritis	1175	2.43	826	1.71	1.42	1.30–1.56
Rheumatoid arthritis with medication	611	1.26	421	0.87	1.45	1.28–1.64
Sjögren syndrome	604	1.24	419	0.86	1.44	1.27–1.63
Sjögren syndrome with medication	110	0.22	72	0.15	1.53	1.14–2.06
Diabetes type 1 with insulin	381	0.78	304	0.62	1.25	1.08–1.46
Ulcerative colitis	367	0.75	282	0.58	1.30	1.12–1.52
Ulcerative colitis with medication	212	0.43	175	0.36	1.22	1.00–1.49
Crohn's disease	298	0.61	235	0.48	1.27	1.07–1.50
Crohn's disease with medication	155	0.32	120	0.24	1.29	1.02–1.64
Polymyalgia rheumatica	287	0.59	233	0.47	1.24	1.04–1.47
Polymyalgia rheumatica with medication	174	0.36	154	0.31	1.13	0.91–1.40
Multiple sclerosis	271	0.55	226	0.46	1.20	1.01–1.43
Multiple sclerosis with medication	99	0.20	96	0.20	1.04	0.78–1.37
Sarcoidosis	266	0.54	124	0.25	2.14	1.73–2.65
Ankylosing spondylitis	263	0.54	194	0.40	1.36	1.13–1.63
Ankylosing spondylitis with medication	82	0.17	64	0.13	1.29	0.93–1.78
Celiac disease	229	0.47	148	0.30	1.55	1.26–1.90
Alopecia areata	198	0.40	152	0.31	1.30	1.05–1.61
Vitiligo	132	0.27	97	0.20	1.36	1.05–1.77
Immune thrombocytopenic purpura	83	0.17	53	0.11	1.56	1.10–2.20
Immune thrombocytopenic purpura with medication	30	0.06	15	0.03	1.96	1.06–3.62
Cutaneous lupus erythematosus	81	0.17	63	0.13	1.29	0.93–1.80
Systemic lupus erythematosus	63	0.13	47	0.10	1.34	0.92–1.95
Systemic lupus erythematosus with medication	41	0.08	30	0.06	1.35	0.85–2.16
Arteritis temporalis	53	0.11	33	0.07	1.63	1.05–2.53
Arteritis temporalis with medication	46	0.09	26	0.05	1.78	1.10–2.89
Bullous pemphigoid	45	0.09	29	0.06	1.54	0.97–2.46
Myasthenia gravis	41	0.08	27	0.06	1.50	0.93–2.44
Wegener's disease	41	0.08	16	0.03	2.51	1.42–4.46
Wegener's disease with medication	28	0.06	12	0.03	2.27	1.16–4.44
Primary biliary cirrhosis	40	0.08	32	0.07	1.24	0.78–1.97
Autoimmune hepatitis	38	0.08	35	0.07	1.10	0.69–1.74
Systemic scleroderma	35	0.07	50	0.10	0.70	0.45–1.08
Autoimmune hemolytic anemia	21	0.04	15	0.03	1.37	0.71–2.65
Behcet's disease	21	0.04	9	0.02	2.42	1.10–5.35
Guillain-Barré syndrome	20	0.04	9	0.02	2.14	0.99–4.66

Incidence rate (IR) in percent to 1000 person-years without a previous diagnosis of the disease. Effect estimates in bold were significant to the 95% confidence interval. *IRR*, incident rate ratio *Weighted events have been rounded, while the estimates used the exact values

COVID-19=1.24, IRR=1.44, 95% CI=1.27–1.63). In addition, the more specific disease definitions with medication led to similar results (Table 2). The highest IRRs, i.e., the largest significant effect estimates, were found for Wegner’s disease (IRR=2.51, 95% CI=1.42–4.46), Behcet’s disease (IRR=2.42, 95% CI=1.10–5.35), sarcoidosis (IRR=2.14, 95% CI=1.73–2.65), and arteritis temporalis (IRR=1.63, 95% CI=1.05–2.53). Wegner’s disease, Behcet’s disease, and arteritis temporalis belong to the group of rare autoimmune diseases involving vasculitis, i.e., small vessel inflammatory processes. Among preselected autoimmune diseases, only systemic scleroderma had IRR estimates below one, but the estimate was not statistically significant (Table 2).

Incidence of diagnosed autoimmune diseases in subgroups

Regarding population subgroups, the IRR for an incident autoimmune disease for persons with COVID-19 compared to those without COVID-19 did not differ significantly across age groups or between men and women. However, the absolute incidence of any first autoimmune disease per 1000 person-years was considerably higher among older than younger persons, e.g., IR=25.04 and IR=19.55, among persons with documented COVID-19 in age groups 65–79 years and above 80 years of age compared to IR=4.17, among persons with documented COVID-19 below 18 years of age. We also observed a higher absolute incidence of any newly diagnosed autoimmune disease among women with COVID-19 (IR =18.02) than among men with COVID-19 (IR =11.33) (Fig. 2).

Among individuals with COVID-19, absolute incidence rates as well as IRR for the COVID-19 group compared to controls for any new autoimmune disease increased according to the severity of the acute COVID-19 disease, ranging from IR=13.96, IRR=1.38, 95% CI=1.32–1.43 among persons


with outpatient treatment for COVID-19, to IR =28.39, IRR=1.75, 95% CI=1.54–1.99 among those hospitalized due to COVID-19, and IR =36.96, IRR=2.28, 95% CI=1.80–2.89 among persons requiring ICU/ventilation (Fig. 2).

Discussion

The excess risk for any newly diagnosed autoimmune disease was 4.50 per 1000 person-years in this study. The highest IRRs were found for rather uncommon autoimmune diseases of the vasculitis group. For the more common autoimmune diseases, the highest estimates were found for rheumatoid arthritis, Sjögren disease, Graves’ disease, and Hashimoto thyroiditis, with an approximately 40% higher rate compared to a matched cohort without SARS-CoV-2 infection. Those without a prior autoimmune disease and COVID-19 had a 43% higher likelihood of developing an incident autoimmune disease than controls, while those with any preexisting autoimmune disease and COVID-19 had a 23% higher likelihood of being diagnosed with another autoimmune disease. As expected, absolute incidence rates (IR) of any autoimmune disease were higher among women compared to men, among older compared to younger individuals and among those with to those without preexisting autoimmune disease. Comparing persons with and without COVID-19, the IRR increased with the severity of COVID-19 as indicated by hospitalization and particularly by ICU/ventilation treatment versus COVID-19 patients in the outpatient sector. Additionally, a higher IRR for a new-onset autoimmune disease was observed in children and adolescents than in adults with/without COVID-19. However, differences between age groups did not reach statistical significance.

Only two other cohort studies were found to investigate the onset of autoimmune diseases after a SARS-CoV-2

Fig. 2 Forest plot comparing incident rate ratios for any first-onset autoimmune disease 3 to 15 months after SARS-CoV-2 infection by subgroup. The severity of COVID-19 was operationalized as only outpatient care, usual hospital care, and ICU/ventilation-intensive care unit and mechanical ventilation



infection. The first investigated 11 endpoints and used medical record data from UK. It reported a hazard ratio of 1.22 (95% CI=1.10–1.34). Due to the median follow-up of only 0.29 years, only 3 of 11 autoimmune diseases were significant [20]. The second study used routine health care data primarily from the USA and found much stronger and more consistent associations between 14 new onset autoimmune diseases and a SARS-Cov-2 infection. However, this previous study used less stringent case definition criteria as one outpatient diagnosis was considered sufficient to define new onset autoimmune disease. In addition, only individuals with newly diagnosed autoimmune diseases within 30 days after the index date were excluded. Both circumstances could lead to exaggerated effect estimates for autoimmune diseases. However, that study also found differences by ethnicity, while the current study using data from Germany reported results mostly for Caucasian [21].

There are several hypotheses regarding the pathogenesis of post-COVID-19, although different mechanisms most likely underlie the complex clinical picture involving multiple organ systems. Drawing parallels to other post-infectious syndromes, possible mechanisms include persistence of the virus or viral remnants, latent virus reactivation, long-lasting tissue damage due to microclotting and chronic inflammation, and autoimmunity [29]. According to current knowledge, autoimmunity following viral infection may be triggered by mechanisms such as epitope spreading, bystander activation, molecular mimicry, and cryptic epitopes [30]. SARS-CoV-2 shares characteristics of other viruses associated with the development of autoimmunity. Acosta-Ampudia and Anaya summarized these hypotheses as follows. (1) Superantigen activity: The S protein of SARS-CoV-2 contains sequence and structure motifs similar to those of a bacterial superantigen and can bind directly to the T-cell receptor. (2) Molecular mimicry: Accumulating evidence demonstrates that the virus has structural similarity to host-derived components. (3) Neutrophil extracellular trap (NET) formation. (4) Type I interferon (IFN) response. (5) “Overt immunity” which describes the appearance of multiple autoantibodies and diverse autoimmune diseases that are significantly associated with SARS-CoV-2 [31]. These mechanisms are in line with several serological studies demonstrating the onset of IgG autoantibodies [32, 33] or emergence of self-reactive B cells [34] as a response to SARS-CoV-2. Moreover, autoantibodies generated during infection are negatively correlated with SARS-CoV-2 antibodies but positively correlated with hyperinflammation markers during acute illness as well as biomarkers for certain post-acute conditions [35]. These findings highlight a potential link between autoreactivity, severity of COVID-19, and susceptibility to post-acute sequelae. Indeed, serological studies have found persisting patterns of autoreactivity in severe COVID-19 cases even after most autoimmunological markers have

subsided after the acute phase [32, 34]. This suggests latent autoimmunity acquired by some patients, which may lead to de novo autoimmune diseases in the long run [22, 33].

Early clinical case studies reported few cases of onset autoimmune diseases following COVID-19. There is growing consensus regarding the relevance of long-term studies on this matter [24], 38. We also found the overall excess risk for a first autoimmune disease to be 4.50 per 1000 person-years, which is much smaller than previously proposed for other potential chronic sequelae of COVID-19. For cardiovascular diseases, the excess risk was 45.29 [11]; for mental diseases, it was 36.48 [12]; and for neurologic disorders, it was estimated to be 70.69 per 1000 people [13]. One reason for this could be that autoimmune diseases are less frequent and the detection time is much longer than that for other diseases. The much larger IRR for hospitalized patients and patients with ICU/ventilation was also reported elsewhere [9, 15].

Strengths and limitations

The main strength of our analysis is its large dataset including more than 600,000 COVID-19 patients and a minimum follow-up period of 3 to 15 months. This unselected sample from all over Germany covers both outpatient and inpatient care and thus constitutes a unique and comprehensive source of evidence. Our analysis is based on confirmed diagnoses documented by ambulatory physicians and hospital discharge diagnosis. Accordingly, our results are not subject to possible distortions resulting from selective, incomplete, or inadequate self-reporting of symptoms but instead rely on information provided by medical professionals. To avoid confounding the relationships between outcomes and exposure, we applied matching on relevant covariates, age, sex, previous autoimmune disease and several prevalent diseases, and utilization of outpatient and inpatient care. The results were confirmed by the fact that estimates of individual outcome definitions were similar with and without additional consideration of disease-specific medication.

Due to the observational nature of our study, we could not determine a causal interpretation of the results. We could not exclude the possibility that our results were affected by unmeasured confounding, although we minimized differences between the COVID-19 and control cohorts by matching. Vaccination status could not be validly assessed in German claims data. Our results may also have been subject to greater symptom awareness of individuals following SARS-CoV-2 infection or detection bias that may have arisen if the health status of individuals after the onset of COVID-19 was more closely monitored and better documented by physicians. Individuals with a mild or asymptomatic course of COVID-19 were likely to be underrepresented in our study because SARS-CoV-2 infections may not

have been documented [36], especially in the first months of the pandemic. The resulting selection of more severe COVID-19 cases may have led to higher incidence estimates in this cohort. In addition, individuals with undocumented SARS-CoV-2 infection may have been included in the control cohort. To the extent that post-COVID also occurred in individuals with undocumented infections, this misclassification induced an overestimation of incidence rates in the control group and, thus, a bias toward the null in estimators of incidence rate ratios.

Conclusion

In this large matched cohort study, COVID-19 was associated with an increased risk of being newly diagnosed with autoimmune disease 3–15 months after SARS-CoV-2 infection. The strength of the association with SARS-CoV-2 infection was most pronounced for autoimmune diseases in the vasculitis group. A more severe course of COVID-19 was associated with a higher likelihood of being newly diagnosed with autoimmune disease. Incident autoimmune diseases were significantly more common in the post-COVID-19 period in all age and sex groups. The autoimmunity hypothesis is supported by a body of evidence linking viral infections to the pathogenesis of autoimmune diseases as well as results from recent clinical and basic research demonstrating persisting autoantibodies and serological autoreactivity following SARS-CoV-2 infection in a subset of patients. Further epidemiologic, clinical, and basic science research is warranted to determine whether SARS-CoV-2 infection triggers the onset of autoimmune disease, to identify the underlying mechanisms and persons at risk, and to investigate effective means of prevention or early treatment.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10067-023-06670-0>.

Code availability The R code of the analysis can be made available upon request by the corresponding author.

Funding Open Access funding enabled and organized by Projekt DEAL. This study is supported by a grant from the German Federal Ministry of Health (Bundesgesundheitsministerium) under Grant Number ZMI1-2521NIK705.

Data availability The raw data used in this study cannot be made available in the manuscript, the supplemental files, or in a public repository due to German data protection laws (Bundesdatenschutzgesetz). The aggregated data is stored on a secure drive at ZEGV.

Compliance with ethical standards

Ethics approval The study was approved by the ethics committee of the TU Dresden (approval number: BO-EK (COVID)-482102021) and adheres to all relevant administrative and legal regulations. The study was registered at [ClinicalTrials.gov](https://www.clinicaltrials.gov) (NCT number: NCT05606198).

Competing interests FT, FE, AV, MS, JJ, BK, LR, CS, and JS and report institutional funding for this project from the German Federal Ministry of Health. Unrelated to this study, JS reports grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK, and Pfizer. He also participated in advisory board meetings for Sanofi, Lilly, and ALK. MB reports payment for data analysis which is presented in this paper from DAK-Gesundheit. Unrelated to this study, MB reports grants from German GBA, Pfizer, and Sanofi Pasteur and consulting fees from Janssen-Cilag. He participated in an advisory board for GSK. The other authors declare that they have no competing interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol* 23:3–20. <https://doi.org/10.1038/s41580-021-00418-x>
- World Health Organization (2021) A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organization
- Global Burden of Disease Long COVID Collaborators (2022) Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. *JAMA* 328:1604–1615. <https://doi.org/10.1001/jama.2022.18931>
- Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong AS, Silverwood RJ, Di Gessa G, Bowyer RC (2022) Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. *Nat Commun* 13:3528. <https://doi.org/10.1038/s41467-022-30836-0>
- Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, Zhang X, Shang L, Zhong J, Wang X, Wang J, Cao B (2022) Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. *Lancet Respir Med* 10:863–876. [https://doi.org/10.1016/s2213-2600\(22\)00126-6](https://doi.org/10.1016/s2213-2600(22)00126-6)
- Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, Taverner T, Chandan JS, Brown K, Simms-Williams N, Shah AD (2022) Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med* 28:1706–1714. <https://doi.org/10.1038/s41591-022-01909-w>
- Magnusson K, Kristoffersen DT, Dell'Isola A, Kiadaliri A, Turkiewicz A, Runhaar J, Bierma-Zeinstra S, Englund M, Magnus PM, Kinge JM (2022) Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. *Nat Commun* 13:7363. <https://doi.org/10.1038/s41467-022-35240-2>
- Franco JVA, Garegnani LI, Oltra GV, Metzendorf MI, Trivisonno LF, Sgarbossa N, Ducks D, Heldt K, Mumm R, Barnes B, Scheidt-Nave C (2022) Long-term health symptoms and sequelae following SARS-CoV-2 infection: an evidence map. *Int J Environ Res Public Health* 19:9915. <https://doi.org/10.3390/ijerph19169915>

9. Al-Aly Z, Xie Y, Bowe B (2021) High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* 594:259–264. <https://doi.org/10.1038/s41586-021-03553-9>
10. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ (2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry* 8:416–427. [https://doi.org/10.1016/s2215-0366\(21\)00084-5](https://doi.org/10.1016/s2215-0366(21)00084-5)
11. Xie Y, Xu E, Bowe B, Al-Aly Z (2022) Long-term cardiovascular outcomes of COVID-19. *Nat Med* 28:583–590. <https://doi.org/10.1038/s41591-022-01689-3>
12. Xie Y, Xu E, Al-Aly Z (2022) Risks of mental health outcomes in people with covid-19: cohort study. *BMJ (Clinical research ed)* 376:e068993. <https://doi.org/10.1136/bmj-2021-068993>
13. Xu E, Xie Y, Al-Aly Z (2022) Long-term neurologic outcomes of COVID-19. *Nat Med* 28:2406–2415. <https://doi.org/10.1038/s41591-022-02001-z>
14. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, Wende D, Vivirito A, Toepfner N, Ehm F, Seifert M (2022) Post-COVID-19-associated morbidity in children, adolescents, and adults: a matched cohort study including more than 157,000 individuals with COVID-19 in Germany. *PLoS Med* 19:e1004122. <https://doi.org/10.1371/journal.pmed.1004122>
15. Xie Y, Bowe B, Al-Aly Z (2021) Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. *Nat Commun* 12:6571. <https://doi.org/10.1038/s41467-021-26513-3>
16. Mizrahi B, Sudry T, Flaks-Manov N, Yehezkeili Y, Kalkstein N, Akiva P, Ekka-Zohar A, Ben David SS, Lerner U, Bivas-Benita M, Greenfeld S (2023) Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. *BMJ* 380:e072529. <https://doi.org/10.1136/bmj-2022-072529>
17. Kocivnik N, Velnar T (2022) A review pertaining to SARS-CoV-2 and autoimmune diseases: what is the connection? *Life* 12(11):1918
18. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A (2021) Diverse functional autoantibodies in patients with COVID-19. *Nature* 595:283–288. <https://doi.org/10.1038/s41586-021-03631-y>
19. Yazdanpanah N, Rezaei N (2022) Autoimmune complications of COVID-19. *J Med Virol* 94:54–62. <https://doi.org/10.1002/jmv.27292>
20. Syed U, Subramanian A, Wraith DC, Lord JM, McGee K, Ghokale K, Nirantharakumar K, Haroon S (2022) The incidence of immune mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. *medRxiv:2022.2010.2006.22280775*. <https://doi.org/10.1101/2022.10.06.22280775>
21. Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ (2023) Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. *EClinicalMedicine* 56:101783. <https://doi.org/10.1016/j.eclinm.2022.101783>
22. Liu Y, Sawalha AH, Lu Q (2021) COVID-19 and autoimmune diseases. *Curr Opin Rheumatol* 33:155–162. <https://doi.org/10.1097/BOR.0000000000000776>
23. Sapkota HR, Nune A (2022) Long COVID from rheumatology perspective - a narrative review. *Clin Rheumatol* 41:337–348. <https://doi.org/10.1007/s10067-021-06001-1>
24. Venkatesan P (2021) NICE guideline on long COVID. *Lancet Respir Med* 9:129. [https://doi.org/10.1016/S2213-2600\(21\)00031-X](https://doi.org/10.1016/S2213-2600(21)00031-X)
25. Ludwig M, Enders D, Basedow F, Walker J, Jacob J (2022) Sampling strategy, characteristics and representativeness of the InGef research database. *Public Health* 206:57–62. <https://doi.org/10.1016/j.puhe.2022.02.013>
26. Hilbe Joseph Michael (2011) Negative binomial regression. In: Cambridge University Press, Cambridge
27. Cameron ACP (2013) Regression analysis of count data. Cambridge University Press, Cambridge
28. R Development Core Team. R: a language and environment for statistical computing. In: R Foundation for Statistical Computing 2019, Vienna, Austria.
29. Choutka J, Jansari V, Hornig M, Iwasaki A (2022) Unexplained post-acute infection syndromes. *Nat Med* 28:911–923
30. Arango M-T, Shoenfeld Y, Anaya JM, Cervera R (2013) Infection and autoimmune diseases. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, Levy RA, Cervera R (eds) Autoimmunity: from bench to bedside. El Rosario University Press, Bogota (Colombia)
31. Acosta-Ampudia Y, Anaya JM (2022) Reply to Cimolai: Post-COVID syndrome and autoimmunity. *J Infect Dis* 226:753–754. <https://doi.org/10.1093/infdis/jiac106>
32. Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, Barman L, Bennett K, Chakraborty S, Chang I (2021) New-onset IgG autoantibodies in hospitalized patients with COVID-19. *Nat Commun* 12:1–15
33. Rojas M, Rodriguez Y, Acosta-Ampudia Y, Monsalve DM, Zhu CS, Li QZ, Ramirez-Santana C, Anaya JM (2022) Autoimmunity is a hallmark of post-COVID syndrome. *J Transl Med* 20:1–5. <https://doi.org/10.1186/s12967-022-03328-4>
34. Woodruff MC, Ramonell RP, Haddad NS, Anam FA, Rudolph ME, Walker TA, Truong AD, Dixit AN, Han JE, Cabrera-Mora M, Runnstrom MC (2022) Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. *Nature* 611:139–147. <https://doi.org/10.1038/s41586-022-05273-0>
35. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA (2022) Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell* 185(881–895):e820. <https://doi.org/10.1016/j.cell.2022.01.014>
36. Gornyk D, Harries M, Glockner S, Strengert M, Kerrinnes T, Heise JK, Maass H, Ortmann J, Kessel B, Kemmling Y, Lange B, Krause G (2021) SARS-CoV-2 seroprevalence in Germany. *Dtsch Arztebl Int* 118:824–831. <https://doi.org/10.3238/arztebl.m2021.0364>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.